Understand local treatment and immune priming
Learn how probe ablation, focused radiation and radioligands deliver injury—and why local control is different from a systemic immune effect.
This guide is for readers who know that treatment can kill a tumor but want to understand where it acts. Start with HLA and prognostic versus predictive evidence if those terms are unfamiliar.
The big ideas
- Ablation and external-beam radiation target a location. Radioligands distribute through the body according to uptake and pharmacology.
- Local injury can release antigens and inflammatory signals. That does not guarantee useful T-cell priming or distant tumor regression.
- Anatomy, dose, disease extent and normal-tissue risk all matter. A lesion-size rule alone cannot choose a treatment.
- The clinical evidence must match the cancer, setting and combination. A positive lung-cancer trial cannot establish a breast-cancer standard.
Follow the questions
| Lesson | Question it answers |
|---|---|
| 1. Injury and immune signals | What is physically damaged, and what could the immune system learn? |
| 2. Timing and disease setting | What is known before deciding whether local treatment fits? |
| 3. Combination evidence | How do we distinguish a rationale from added clinical benefit? |
| 4. Read a proposal | Which evidence and safety gates must a proposal answer? |
| 5. Measure the result | What do imaging and biopsies actually establish? |
| 6. Compare the tools | Which physical and biological differences matter? |
Keep the evidence in its setting
BOOSTER randomized ablation plus checkpoint inhibition against checkpoint inhibition alone in advanced non-small-cell lung cancer (NSCLC). It is not an SBRT (stereotactic body radiation therapy) trial. PACIFIC established benefit from durvalumab after conventional chemoradiotherapy in a different NSCLC setting. Neither establishes a universal local-treatment-plus-checkpoint schedule for TNBC.
Randomized breast-cancer evidence is an essential counterweight: NRG-BR002 did not demonstrate a progression-free or overall survival benefit from metastasis-directed treatment in its studied oligometastatic population; CURB did not demonstrate a benefit in its breast cohort. Local treatment can still have roles such as symptom relief or selected local control. The purpose and supporting evidence must be explicit.
A peer journey can show what questions arose. Sid received dostarlimab and ipilimumab before and during his radioligand course; describing that as “RLT (radioligand therapy) without ICI” was incorrect. Simultaneous interventions and changing disease make one patient’s response unsuitable for assigning causality to one treatment.
Applied to Diana
Use the current care plan and the local-priming question for decisions. This guide supplies vocabulary and evidence boundaries; it carries no treatment schedule or vendor commitment.
Takeaway: Ask separately whether a treatment controls the treated site and whether the exact combination improves a meaningful patient outcome.
Vocabulary: HLA means human leukocyte antigen.
Sources and scope
General teaching, source-checked October 8, 2026. Expert and learner review remain pending. These lessons explain mechanisms and study interpretation; current choices are owned by the care plan and the local-priming question.
- BOOSTER randomized ablation-plus-immunotherapy trial in advanced NSCLC.
- Primary TREX1 radiation-dose study.
- PACIFIC: durvalumab after chemoradiotherapy in unresectable stage III NSCLC.
- CURB randomized trial; benefit in NSCLC, no demonstrated benefit in the breast cohort.